This inventor holds 2 USPTO granted patents. Top assignee: Allen Hanburys Limited. Active years: 1976-1977.
Location History:
- Newcastel-upon-Tyne, EN (1976)
- Newcastle-upon-Tyne, EN (1977)
Company Filing History:
Years Active: 1976-1977
Title: Norman James Harper: Innovator in Oral Analgesics
Introduction
Norman James Harper is a notable inventor based in Newcastle Upon Tyne, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds with analgesic properties. With a total of 2 patents to his name, Harper's work has the potential to impact pain management therapies.
Latest Patents
Harper's latest patents include innovative compounds such as ethylene diamine derivatives. These compounds are characterized by a complex general formula that allows for various substitutions, making them versatile in their applications. They have been identified as having utility as oral analgesics, which could provide new options for pain relief. Another significant patent is for 1-(3,4-Dichlorobenzamidomethyl)-cyclohexyldimethylamine, which also falls under the category of oral analgesics. The detailed chemical structures and functionalities of these compounds highlight Harper's expertise in medicinal chemistry.
Career Highlights
Harper is currently associated with Allen Hanburys Limited, where he continues to innovate in the pharmaceutical sector. His work focuses on creating effective analgesic compounds that can improve patient outcomes. His dedication to research and development has positioned him as a key figure in his field.
Collaborations
Harper collaborates with fellow inventor George Bryan Veitch, contributing to a dynamic exchange of ideas and expertise in their projects. Their partnership enhances the innovative potential of their work in the pharmaceutical industry.
Conclusion
Norman James Harper's contributions to the field of oral analgesics through his patents demonstrate his commitment to advancing medical science. His innovative compounds have the potential to significantly improve pain management therapies.